Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study

PURPOSE: COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wav...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoliaroff-Pepin, Anna, Peine, Caroline, Herath, Tim, Lachmann, Johannes, Hellenbrand, Wiebke, Perriat, Delphine, Dörre, Achim, Nitsche, Andreas, Michel, Janine, Grossegesse, Marica, Hofmann, Natalie, Rinner, Thomas, Kohl, Claudia, Brinkmann, Annika, Meyer, Tanja, Stern, Daniel, Treindl, Fridolin, Dorner, Brigitte G., Hein, Sascha, Werel, Laura, Hildt, Eberhard, Gläser, Sven, Schühlen, Helmut, Isner, Caroline, Peric, Alexander, Ghouzi, Ammar, Reichardt, Annette, Janneck, Matthias, Lock, Guntram, Huster, Dominik, Grünewald, Thomas, Schaade, Lars, Wichmann, Ole, Harder, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009838/
https://www.ncbi.nlm.nih.gov/pubmed/36913112
http://dx.doi.org/10.1007/s15010-023-02012-z
Descripción
Sumario:PURPOSE: COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave. METHODS: We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates. RESULTS: 21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12–78%), 81.5% (95% CI: 68–90%) and 95.6% (95%CI: 88–99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses. CONCLUSION: Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s15010-023-02012-z.

Ejemplares similares